middle.news
Paradigm’s clinical setback opens a possible restructuring path
9:47am on Wednesday 30th of September, 2026 AEST
•
Biotechnology
Read Story
Paradigm’s clinical setback opens a possible restructuring path
9:47am on Wednesday 30th of September, 2026 AEST
Key Points
FTI Consulting appointed to control Paradigm’s business and assets
Phase 3 PARA_OA_012 trial will not proceed as planned
Potential deed of company arrangement remains subject to creditor approval
ASX says Paradigm’s financial condition is inadequate for continued quotation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE